Metastatic castration-sensitive prostate cancer with BRCA2 mutation

Metastatic castration-sensitive prostate cancer with a BRCA2 mutation represents an advanced male genitourinary malignancy that has spread beyond the prostate to regional lymph nodes, bones, or visceral organs while retaining biological responsiveness to testosterone-lowering therapies

Metastatic castration-sensitive prostate cancer with a BRCA2 mutation represents an advanced male genitourinary malignancy that has spread beyond the prostate to regional lymph nodes, bones, or visceral organs while retaining biological responsiveness to testosterone-lowering therapies Disruption of this pathway results in genomic instability, impaired repair of double-strand DNA breaks, and a clinically aggressive disease phenotype characterized by early metastatic dissemination, rapid progress...

Metastatic castration-sensitive prostate cancer with a BRCA2 mutation represents an advanced male genitourinary malignancy that has spread beyond the prostate to regional lymph nodes, bones, or visceral organs while retaining biological responsiveness to testosterone-lowering therapies

This subtype is defined by deleterious germline or somatic alterations in the *BRCA2* tumor suppressor gene, an essential component of homologous recombination DNA repair Disruption of this pathway results in genomic instability, impaired repair of double-strand DNA breaks, and a clinically aggressive disease phenotype characterized by early metastatic dissemination, rapid progression, and heightened susceptibility to targeted poly(ADP-ribose) polymerase inhibition

This subtype is defined by deleterious germline or somatic alterations in the *BRCA2* tumor suppressor gene, an essential component of homologous recombination DNA repair